ArticleThe journal of allergy and clinical immunology. Global2026
Consistent adherence to biologic therapies is critical for improving outcomes in asthma.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Evidence on real-world adherence to asthma biologic therapies and the relevance to clinical outcomes in asthma is limited. Objective: We sought to evaluate biologic use patterns and the relationships between adherence, clinical, and health care resource utilization (HCRU) outcomes and economic burden in patients with asthma. Methods: This was a retrospective observational study using Optum's de-identified Market Clarity Data (Optum Market Clarity) from 2007 to 2023 in adults in the United States with an asthma diagnosis in the 12 months before the first biologic dose (index date) who had ≥12 months of follow-up. Medication possession ratio (MPR; number of doses taken/dosing intervals) and group-based trajectory modeling (GBTM) identified distinct patient adherence patterns and assessed impact on exacerbations, HCRU, and costs (all-cause/asthma-related). Results: Overall, 10,088 eligible patients were included in the MPR analysis; 54.7% discontinued treatment, 5.2% were minimally adherent, 20.3% were partially adherent, and 19.8% were adherent. Of these, 9,553 did not switch biologic during follow-up and were included in the GBTM analysis. For patients with 1 or more follow-up doses (n = 8,151), MPRs revealed suboptimal biologic adherence (average range, 40.6%-64.0%). GBTM identified 7 adherence clusters, with distinct adherence trajectories categorized from highest to lowest levels of biologic adherence. Patients with the highest adherence generally demonstrated the best outcomes. In patients in less adherent groups, increases were seen in exacerbations defined by asthma-related hospitalizations, all-cause HCRU, and all-cause health care costs. HCRU and asthma-related costs were generally lower for patients with the highest adherence. Conclusions: Treatment adherence was consistently associated with better all-cause and asthma-related outcomes, highlighting the importance of biologic adherence in patients with asthma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.